Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists

Because of concerns about the safety of long-acting β2-agonists (LABAs) in asthma management, the Food and Drug Administration (FDA) in 2010 issued a public health advisory stating that LABAs should not be used as first-line therapy for asthma, and a boxed warning was required for all products…

https://ift.tt/2KkM4AA